Screening for pancreatic cancer in familial high-risk individuals: A systematic review

Table 2 Non-controlled studies on pancreatic cancer screening

Study (author/year)	Country	Study population n (HRIs%)	Period of time	Pancreatic tumor, n (%)	PC/death, n (%)
Langer et al[17], 2009	Germany	76 (100)	5 yr	6 (7.9)	0 (0)/0 (0)
Rulyak et al[18], 2001	United States	35 (100)	2 yr	12 (34.3)	0 (0)/0 (0)
Sud et al[19], 2014	United States	30 (63.3)	3 yr	3 (10)	2 (6.7)/0 (0)
Al-Sukhni et al[20], 2012	Canada	262 (60.9)	8 yr	84 (32.1)	3 (1.1)/2 (0.8%)
Verna et al[21], 2010	United States	51 (100)	3 yr	20 (39.2)	2 (3.9)/0 (0)
Poley et al[22], 2009	Netherland	44 (47.7)	2 yr	10 (22.7)	3 (6.8)/2 (4.5)
Ludwig et al[23], 2011	United States	109 (100)	7 yr	9 (8.3)	1 (0.9)/0 (0)
Brentnall et al[24], 1999	United States	14 (100)	15 mo	7 (50)	0 (0)/0 (0)
Canto et al[25], 2012	United States	216 (90)	28.8 mo	92 (45.6)	0 (0)/0 (0)

Pancreatic tumors include cystic adenoma, PC, IPMN, PanIN, neuroendocrine tumor. PC: Pancreatic cancer; HRIs: Familial high-risk individuals.